Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enterix, a wholly-owned subsidiary of Quest Diagnostics, has announced the availability of the InSure Quik F I T fecal immunochemical test, a point-of-care version of the company's lab-based InSure FIT test that provides physicians with the sensitivity and specificity of the laboratory-based InSure FIT test.
Subscribe to our email newsletter
The availability of the CLIA-waived InSure Quik F I T test is intended to help physicians increase patient compliance with an annual colorectal cancer screening test. In addition to sensitivity and specificity, the unique features of the InSure family of tests have been shown to increase patient compliance with annual colorectal cancer screening programs.
InSure FIT and InSure Quik F I T feature a unique long-handled blue brush to collect two water-based samples – rather than the solid samples required by other FIT or FOBT tests. In addition, InSure Quik F I T does not require any change in patient diet or medication, enhancing its ease of use.
Stephen Suffin, interim chief laboratory officer, Quest Diagnostics, said: “The availability of InSure Quik F I T reinforces two of our company’s priorities – providing physicians and patients with diagnostic insights that can help improve preventive care, and improving and simplifying patient care with a growing portfolio of point-of-care testing options.”